ter these response periods, they complained distension of the abdomen. Abdominal CT scan detected ascites, but there found no other recurrent site than peritoneum. Cytological examination of ascites, lung adenocarcinoma was confirmed. Two patients had isolated peritoneal relapse, and one had peritoneal and meningeal relapse (8) . They had supportive care only because of their poor performance status.
Metastatic involvement of the peritoneum in lung cancer patients is not a very rare autopsy finding (9) . Based on previous reports, the incidence of carcinomatous peritonitis ranges from 2.7% to 16% in all lung cancer patients (9) . Nevertheless, carcinomatous peritonitis from lung cancer is infrequently encountered and clinical reports concerning this distant metastasis are rare. We previously reported that 12 (1.2%) of 1041 patients with lung cancer had carcinomatous peritonitis (6) . In our hospital, 3 (2.0%) of 153 consecutive lung cancer developed carcinomatous peritonitis in recent three years, and all of them were recurrent elderly cases after effective therapy with EGFR-TKIs. To our best knowledge, there were two previous cases, who were successfully treated with EFGR-TKI in lung adenocarcinoma patients with carcinomatous peritonitis (6,7). On the other hand, however, there has no patient with peritoneal recurrence after successfully treatment with EGFR-TKIs such as ours. The existence of two different responses, good responded peritonitis with EGFR-TKTs and peritoneal recurrence after good response to EGFR-TKIs, se- Although very rare, peritoneum is one of possible sites of relapse in NSCLC patients. In the era of EGFR-TKIs for EGFR mutated patients including the elderly, patients with peritoneal relapse may increase in number. Our results suggest that such recurrence might be related to insufficient concentration of EGFR-TKIs in these sites. Clinicians should be careful about peritoneal recurrence after successful treatment with EFFR-TKIs. Such rare relapse may also be observed in the elderly patients.
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